Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases.
The Pulmonary Hypertension Association Europe (PHA EU) has launched ‘Time Matters’ a new campaign which encourages people with Pulmonary Hypertension (PH) and their friends and family to share hopes and dreams for the future in order to raise awareness of this deadly and rapidly progressive condition. By logging on to the website http://phtimematters.org and posting an entry, everybody can help the patient association take a step towards increased awareness and understanding of this devastating condition.
UCLA researchers have found that the hormone estrogen may help reverse advanced pulmonary hypertension, a rare and serious condition that affects 2 to 3 million individuals in the U.S., mostly women, and can lead to heart failure.
A new report from scientists at Massachusetts General Hospital (MGH) and their colleagues in centers around the world finds that common variants in 28 regions of DNA are associated with blood pressure in human patients.
Sagene Pharmaceuticals, Inc., a biopharmaceutical company focused on developing combinations of FDA-approved drugs to treat diseases associated with aging, has completed a pre-IND meeting with the Division of Reproductive and Urologic Products of the FDA to discuss the development plan for SPI-1972, a dual-action combination treatment for erectile dysfunction.
New ESC guidelines emphasise the importance of screening and risk assessment. Pre-existing heart disease is rarely a contraindication to pregnancy - indeed, many women with heart disorders tolerate pregnancy well - but it remains a "major concern" that complications are frequent and in some cases may be life-threatening for both the mother and her child. In Europe maternal heart disease has now become the major cause of maternal death during pregnancy.
United Therapeutics Corporation announced today the completion of its FREEDOM-C(2) Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension.
Children born with heart defects that pummel their lungs with up to three times the normal blood volume quickly find their lungs in jeopardy as well.
The Canadian Association of PNH Patients applauds governments across Canada for their landmark agreement to provide public access to Soliris (eculizumab), a life-saving treatment for the ultra-rare blood disease known as paroxysmal nocturnal haemoglobinuria.
Merck, known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin.
Pediatric cardiologists are prone to misinterpreting electrocardiograms when using the results to determine whether young athletes have heart defects that could make exercising perilous, according to a new study from the Stanford University School of Medicine and Lucile Packard Children's Hospital. This is the first research to examine the acumen of pediatric cardiologists from several health-care institutions in using ECGs to detect rare heart conditions associated with sudden cardiac death.
A new study by researchers at Hospital for Special Surgery has identified patients who are at a higher risk of morbidity and mortality when undergoing knee replacement surgery in both legs at the same time.
The Affordable Care Act was signed into law March 23, 2010, with the aim of extending medical coverage to more Americans. The law has been a political football, and arguments continue to rage over whether it's good or bad for the country. This, however, is simply the story of how it affected one person.
Arena Pharmaceuticals, Inc. announced today results from a Phase 1 clinical trial of APD811, an orally bioavailable agonist of the prostacyclin receptor which is intended for the treatment of pulmonary arterial hypertension, or PAH.
One-fifth of all patients with pulmonary arterial hypertension suffer with the fatal disease for more than two years before being correctly diagnosed and properly treated, according to a new national study led by researchers at Intermountain Medical Center in Salt Lake City.
Two-year-old Owen Stark came to St. Louis Children's Hospital in the summer of 2010 near death from heart failure and dangerously high blood pressure in his lungs.
Actelion Pharmaceuticals US, Inc. and the ENTELLIGENCE Steering Committee recognized four young researchers and their mentors for their efforts in advancing research in PAH. Each researcher will receive a 12-month mentored grant of up to $100,000 in support, funded through the ENTELLIGENCE program supported by Actelion. The announcement was made at an awards luncheon, during which the recipients of the 2011 awards gave an overview of their proposed work.
United Therapeutics Corporation announced today the completion of its FREEDOM-M Phase 3 trial of treprostinil diethanolamine, an investigational sustained release oral formulation of treprostinil, a stable synthetic form of prostacyclin, in patients with pulmonary arterial hypertension (PAH).
Pulmonary hypertension (PH) is a rare, often incurable lung disorder that affects individuals of all ages, races and ethnic backgrounds. In the recent 4th World Conference on Pulmonary Hypertension held by the WHO, PH was classified into five groups based on its causes, highlighting both the magnitude of conditions associated with PH and how little we know of the etiology in many cases.
Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.